Summit Therapeutics is a biotechnology business based in the US. Summit Therapeutics shares (SMMT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.84 – an increase of 15.56% over the previous week. Summit Therapeutics employs 105 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $21.84 |
|---|---|
| 52-week range | $1.64 - $33.89 |
| 50-day moving average | $17.32 |
| 200-day moving average | $8.38 |
| Wall St. target price | $28.25 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.11 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $20.25 from 2024-10-14
| 1 week (2024-10-09) | 7.14% |
|---|---|
| 1 month (2024-09-16) | -31.31% |
| 3 months (2024-07-16) | 122.04% |
| 6 months (2024-04-16) | 472.03% |
| 1 year (2023-10-16) | 1,057.14% |
|---|---|
| 2 years (2022-10-14) | 1,645.69% |
| 3 years (2021-10-13) | 277.80% |
| 5 years (2019-10-16) | 1,173.58% |
| Gross profit TTM | $705,000 |
|---|---|
| Return on assets TTM | -31.01% |
| Return on equity TTM | -102.77% |
| Profit margin | 0% |
| Book value | $0.27 |
| Market Capitalization | $14.9 billion |
TTM: trailing 12 months
We're not expecting Summit Therapeutics to pay a dividend over the next 12 months.
Summit Therapeutics's shares were split on 20 September 2020.
Over the last 12 months, Summit Therapeutics's shares have ranged in value from as little as $1.64 up to $33.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Summit Therapeutics's is -0.974. This would suggest that Summit Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Summit Therapeutics has bucked the trend.
Summit Therapeutics Inc. , a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.